Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

Autor: Choi J; Division of Oncodermatology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Anderson R; Faculty of Health Sciences, Department of Immunology, University or Pretoria, Corner Doctor Savage Road and Bophelo Road, PO Box 667, Pretoria, 0002, South Africa., Blidner A; Laboratory of Immunopathology, Institute of Biology and Experimental Medicine-CONICET, Buenos Aires, Argentina., Cooksley T; Manchester University Foundation Trust, Manchester, UK.; The Christie, University of Manchester, Manchester, UK., Dougan M; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Glezerman I; Renal Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Ginex P; Oncology Nursing Society, Pittsburgh, PA, USA., Girotra M; Endocrine Division, Department of Medicine, Weill Cornell Medical College (MG, AF), New York, NY, USA.; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Gupta D; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Johnson D; Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA., Shannon VR; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Suarez-Almazor M; Section of Rheumatology and Clinical Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rapoport BL; Faculty of Health Sciences, Department of Immunology, University or Pretoria, Corner Doctor Savage Road and Bophelo Road, PO Box 667, Pretoria, 0002, South Africa. bernardo.rapoport@up.ac.za.; The Medical Oncology Centre of Rosebank, 129 Oxford Road, Saxonwold, 2196, Johannesburg, South Africa. bernardo.rapoport@up.ac.za., Lacouture ME; Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Outpatient Center, New York, NY, USA.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Dec; Vol. 28 (12), pp. 6119-6128. Date of Electronic Publication: 2020 Aug 27.
DOI: 10.1007/s00520-020-05706-4
Abstrakt: Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.
Databáze: MEDLINE
Externí odkaz: